The development and validation of a dissolution method for clomipramine solid dosage forms

Dissolution Technologies

Volumn 11, Issue 3, 2004, Pages 16-24

  Ansari, Mehdi ^a   Kazemipour, Maryam ^b   Talebnia, Javad ^a  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; GENERIC DRUG;

AREA UNDER THE CURVE; ARTICLE; DISSOLUTION; DRUG CAPSULE; DRUG COATING; DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG SOLUBILITY; MEAN DISSOLUTION TIME; MEAN RESIDENCE TIME; ULTRAVIOLET SPECTROPHOTOMETRY; VALIDATION STUDY;

EID: 84962094453     PISSN: 1521298X     EISSN: None     Source Type: Journal    
DOI: 10.14227/DT110304P16     Document Type: Article

References (19)

1. C. K. Carrico," Workshop report-AAPS: USP workshop on dissolution calibration and testing," Pharm. Res. 13(1996) 6-9.
2. V. P. Shah, L. J. Lesko, J. Fan, N. Fleischer, J. Handerson, H. Malinowski, M. Makary, L. Ouderkirk, S. Roy, P. Sathe, G. J. P. Singh, L. Tillman, Y. Tsong, R. L. Williams," FDA guidance for industry: dissolution testing of immediate release solid oral dosage forms," Dissolution Technol. 4(1997) 15-22.
3. B. Hoener, L. Z. Benet, in: G. S. Banker, C. T. Rhodes (Eds.), Modern Pharmaceutics, Marcel Dekker, New York, (1990), pp. 143.
4. E. D. Jorgensen, D. Bhagwat, Pharm. Sci. Technol. Today 1 (1998) 128-135.
5. USP 25, the United States Pharmacopeial Convention, Rockville, MD, USA, (2002), pp. 2011-2012 and 2258-2259.
6. The European Pharmacopoeia, fourth ed., Council of Europe, Strasbourg, (2002), pp. 194-197.
7. FDA, Guidance for Industry: Dissolution testing of Immediate Release Solid Oral Dosage Forms, (1997).
8. International Pharmaceutical Federation (FIP) guidelines for dissolution testing of solid oral products, Drug Inf. J. 30 (1996) 1071-1084.
9. S. A. Qureshi, I. J. McGilveray," Typical variability in drug dissolution testing: study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product," Eur. J. Pharm. Sci. 7 (1999) 249-258.
10. A. Frick, H. Moller, E. Wirbitzki," Biopharmaceutical characterization of oral immediate release drug products. In vitro/in vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin," Eur. J. Pharm. Biopharm. 46 (1998) 305-311.
11. E. Galia, E. Nicolaides, D. Horter, R. Lobenberg, C. Reppas, J. B. Dressman," Evaluation of various dissolution media for predicting in vivo performance of class 1 and II drugs," Pharm. Res. 15 (1998) 698-705.
12. V. J. Stella, S. Martodihardjo, K. Terada, M. R. Venkatramana," Some relationships between the physical properties of various 3-acyloxymethyl prodrugs of phenytoin to structure: potential in vivo performance implication," J. Pharm. Sci. 87 (1998) 1235-1241.
13. F. Podczeck," Comparison of in vitro dissolution profiles by calculating mean dissolution time (MDT) or mean residence time (MRT)," Int. J. Pharm. 97(1993) 93-100.
14. J. E. Polli, G. S. Rekhi, L. L. Augsburger, V. P. Shah, "Methods to compare dissolution profiles and a rationale for wide dissolution specifications for metoprolol tartrate tablets," J. Pharm. Sci. 86(1997) 690-700.
15. J. W. Moore, H. H. Flanner," Mathematical comparison of dissolution profiles," Pharm. Technol. June (1996) 64-74.
16. V. P. Shah, Y. Tsong, P. Sathe, R. L. Williams," Dissolution profile comparison using similarity factor, f2," Dissolution Technol. 6(1999) 15.
17. P. M. Sathe, Y. Tsong, V. P. Shah," In vitro dissolution profile comparison: statistics and analysis, model dependent approach," Pharm. Res. 13(1996) 1799-1803.
18. V. P. Shah, Y. Tsong, P. Sathe, J. P. Liu," In vitro dissolution profile comparison statistics and analysis of the similarity factor, f2." Pharm. Res. 15(1998) 889-896.
19. J. W. Mauger, D. Chilko, S. Howard," On the analysis of the dissolution data," Drug Dev. Ind. Pharm. 12(1986) 969-992.